Monday, October 11, 2004

Endovasc Enacts Sarbanes-Oxley Compliant Initiative; Business Development Company Adopts New Code of Ethics

Endovasc Inc. (OTCBB: EVSC), a drug development company that has pioneered new cardiovascular and metabolic drug therapies, announces that as a Business Development Company its senior executives and financial officers have adopted a more stringent code of ethics that maintains the standards of business conduct to ensure compliance within the legal requirements of the Sarbanes-Oxley Act of 2002, specifically Section 406.

In addition to compliance with legal requirements, the purpose of adopting this code is to deter wrongdoing and promote ethical conduct, including full, fair, accurate and understandable disclosure of financial information in the periodic reports of the Company.

According to Dwight Cantrell, CFO of Endovasc, Inc., "The matters covered in this Code are of the utmost importance to the Company, our stockholders and our business partners, and are essential to our ability to conduct our business in accordance with our stated values. Financial executives hold an important and elevated role in corporate governance and are uniquely capable and empowered to ensure that stockholders' interests are appropriately balanced, protected and preserved. Accordingly, this Code provides principles to which financial executives are expected to adhere and advocate. This Code embodies rules regarding individual and peer responsibilities, as well as responsibilities to the company, the public and others."

Endovasc Enacts Sarbanes-Oxley Compliant Initiative; Business Development Company Adopts New Code of Ethics

Send to a friend:

0 Comments: